에서 실시간으로 운영 중이에요! 자세히 알아보기

Scorpius Holdings, Inc.

SCPX

시가총액 US$39.4만

상장 폐지됨

SCPX은(는) 2025년 4월 21일에 상장 폐지됐어요.

순위로 돌아가기

소개: Scorpius Holdings Inc is an integrated contract development and manufacturing organization (CDMO) focused on rapidly advancing biologic and cell therapy programs to the clinic and beyond. It offers a broad array of analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its state-of-the-art facilities.

직원 수: 84

건강관리 제약 - 종합

뉴스

긍정적

중립

부정적

투자 심리 3개월

긍정적 0%

중립 0%

부정적 0%

NYSE American to Commence Delisting Proceedings Against Scorpius Holdings, Inc. (SCPX)

NEW YORK--(BUSINESS WIRE)--NYSE American LLC (“NYSE American” or the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of Scorpius Holdings, Inc. (the “Company”) — ticker symbol SCPX — from NYSE American. Trading in the Company's common stock will be suspended immediately. NYSE Regulation has determined that the Company is no longer suitable for listing pursuant to Section 1003(f)(v) of the NYSE American Company Guide.

NYSE American to Commence Delisting Proceedings Against Scorpius Holdings, Inc. (SCPX)

Scorpius Holdings Engages Alliance Global Partners to Explore Strategic Alternatives

DURHAM, N.C., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract development and manufacturing organization ("CDMO"), today announced that it has engaged Alliance Global Partners (“A.G.P.”) to assist in exploring strategic alternatives for the Company. This engagement is part of the Company's ongoing efforts to maximize shareholder value and evaluate a range of potential strategic opportunities. Scorpius' leadership remains committed to leveraging its scientific and technical expertise to enhance its position in the biomanufacturing sector while considering various avenues to drive long-term growth.

Scorpius Holdings Engages Alliance Global Partners to Explore Strategic Alternatives

Scorpius Holdings Announces Collaboration with KaloCyte to Advance Manufacturing for ErythroMer™

Partnership highlights Scorpius' expertise in supporting innovative therapeutic programs Partnership highlights Scorpius' expertise in supporting innovative therapeutic programs

Scorpius Holdings Announces Collaboration with KaloCyte to Advance Manufacturing for ErythroMer™

Scorpius Holdings Cancels Planned Reverse Stock Split

DURHAM, N.C., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract development and manufacturing organization (“CDMO”), today announced that the Company's planned 1-for-20 reverse stock split (the “Reverse Stock Split”) of its common stock (the “Common Stock”) that was announced yesterday, will not be effectuated.

Scorpius Holdings Cancels Planned Reverse Stock Split

Scorpius Holdings Announces Reverse Stock Split

DURHAM, N.C., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract development and manufacturing organization (“CDMO”), today announced that the Company's Board of Directors approved a 1-for-20 reverse stock split (the “Reverse Stock Split”) of the Company's common stock (the “Common Stock”), to increase the selling price of the Company's Common Stock in order to maintain compliance with the requirements and policies of the NYSE American.

Scorpius Holdings Announces Reverse Stock Split

Scorpius Holdings Launches Scorpius Ventures to Support U.S. Biotech Innovation through Flexible Equity-Based Onshoring Model

New business unit offers services for promising biotech companies through combined fee-for-service and equity-based model, fostering partnerships that align with BIOSECURE Act goals to onshore and strengthen U.S.-based biosecurity and production capacity New business unit offers services for promising biotech companies through combined fee-for-service and equity-based model, fostering partnerships that align with BIOSECURE Act goals to onshore and strengthen U.S.-based biosecurity and production capacity

Scorpius Holdings Launches Scorpius Ventures to Support U.S. Biotech Innovation through Flexible Equity-Based Onshoring Model

Scorpius Holdings Reports Third Quarter 2024 Results, Highlighting Strategic Partnerships, Cost Savings, and Progress Toward Profitability

DURHAM, N.C., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract development and manufacturing organization (“CDMO”), today provided a strategic, financial, and operational update for the third quarter ended September 30, 2024.

Scorpius Holdings Reports Third Quarter 2024 Results, Highlighting Strategic Partnerships, Cost Savings, and Progress Toward Profitability

Scorpius Holdings Announces Collaboration with Celltheon Corporation, a U.S.-Based Cell Line Development Company; First Client Signed Under New Partnership Agreement

DURHAM, N.C., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract development and manufacturing organization ("CDMO"), today announced a partnership with Celltheon Corporation to provide cell line development services to clients using Celltheon's proprietary GOLDILOCKS™ transposase-based platform.

Scorpius Holdings Announces Collaboration with Celltheon Corporation, a U.S.-Based Cell Line Development Company; First Client Signed Under New Partnership Agreement

Scorpius Holdings Announces Implementation of New Cost Savings Measures Expected to Save Over $2 Million Annually

DURHAM, N.C., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (“Scorpius” or the “Company”), an integrated biomanufacturing company, today announced the implementation of strategic cost-saving measures expected to save over $2 million annually.

Scorpius Holdings Announces Implementation of New Cost Savings Measures Expected to Save Over $2 Million Annually

Scorpius Selected for Rapid Response Partnership Vehicle (RRPV) to Accelerate Medical Countermeasure Development in Support of BARDA

Collaboration Aims to Expedite the Development of Critical Solutions for Public Health Threats, Including Pandemic Preparedness and Emerging Infectious Diseases Collaboration Aims to Expedite the Development of Critical Solutions for Public Health Threats, Including Pandemic Preparedness and Emerging Infectious Diseases

Scorpius Selected for Rapid Response Partnership Vehicle (RRPV) to Accelerate Medical Countermeasure Development in Support of BARDA

뉴스 순위 보기

Lightweight Charts™를 사용해 가격 차트를 구현했어요.